Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy

Barbara Muz; Feda Azab; Mark Fiala; Justin King; Daniel Kohnen; William E. Fogler; Ted Smith; John L. Magnani; Ravi Vij; Abdel Kareem Azab

doi:10.1038/s41408-019-0227-3

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy

Barbara Muz, Feda Azab, Mark Fiala, Justin King, Daniel Kohnen, William E. Fogler, Ted Smith, John L. Magnani, Ravi Vij, Abdel Kareem Azab

Research output: Contribution to journal › Letter › peer-review

19 Scopus citations

Original language	English
Article number	68
Journal	Blood cancer journal
Volume	9
Issue number	9
DOIs	https://doi.org/10.1038/s41408-019-0227-3
State	Published - Sep 1 2019

Access to Document

10.1038/s41408-019-0227-3

Cite this

@article{441e8414a1fa414888ca8d41a61c4f42,

title = "Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy",

author = "Barbara Muz and Feda Azab and Mark Fiala and Justin King and Daniel Kohnen and Fogler, {William E.} and Ted Smith and Magnani, {John L.} and Ravi Vij and Azab, {Abdel Kareem}",

note = "Funding Information: GMI-1271 and GMI-1359 antagonists were provided by GlycoMimetics Inc. (Rockville, MD). The study was supported partially by a research grant from GlycoMimetics, Inc. and by the award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH (U54CA199092). The imaging studies were supported by NIH P50 CA094056 (Molecular Imaging Center) and NCI P30 CA091842 (Siteman Cancer Center Small Animal Cancer Imaging shared resource). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.",

year = "2019",

month = sep,

day = "1",

doi = "10.1038/s41408-019-0227-3",

language = "English",

volume = "9",

journal = "Blood cancer journal",

issn = "2044-5385",

number = "9",

}

TY - JOUR

T1 - Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy

AU - Muz, Barbara

AU - Azab, Feda

AU - Fiala, Mark

AU - King, Justin

AU - Kohnen, Daniel

AU - Fogler, William E.

AU - Smith, Ted

AU - Magnani, John L.

AU - Vij, Ravi

AU - Azab, Abdel Kareem

N1 - Funding Information: GMI-1271 and GMI-1359 antagonists were provided by GlycoMimetics Inc. (Rockville, MD). The study was supported partially by a research grant from GlycoMimetics, Inc. and by the award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH (U54CA199092). The imaging studies were supported by NIH P50 CA094056 (Molecular Imaging Center) and NCI P30 CA091842 (Siteman Cancer Center Small Animal Cancer Imaging shared resource). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

PY - 2019/9/1

Y1 - 2019/9/1

UR - http://www.scopus.com/inward/record.url?scp=85070893983&partnerID=8YFLogxK

U2 - 10.1038/s41408-019-0227-3

DO - 10.1038/s41408-019-0227-3

M3 - Letter

C2 - 31431613

AN - SCOPUS:85070893983

SN - 2044-5385

VL - 9

JO - Blood cancer journal

JF - Blood cancer journal

IS - 9

M1 - 68

ER -

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy

Access to Document

Other files and links

Cite this